From Vinodksingh

Contents 1 Overview 1.1 GSK3beta 1.1.1 Structural details 1.1.2 Phosphorylation 1.1.3 Similarity 1.1.4 Amino Acid Sequence 1.1.5 Others Details 1.1.6 GOR4 result for : UNK_163320

Overview

Glycogen synthase kinase-3 (GSK-3) has recently emerged, in the field of medicinal chemistry, as one of the most attractive therapeutic targets for the development of selective inhibitors as promising new drugs for numerous serious pathologies, including Alzheimer's disease, stroke, bipolar disorders, chronic inflammatory processes, cancer, alopepia and Type II diabetes. The full potential of GSK-3 inhibitors is yet to be realised and the number of drug candidates being developed by both academic centres and pharmaceutical companies has increased exponentially in the last three years. This review discloses recent discoveries on peptides and small molecules targeting GSK-3. Antisense therapy for the modulation of GSK-3 expression is also discussed. Focusing attention on this exciting target could thus reap considerable clinical and economic rewards.

GSK3beta

Structural details

• GSK3 has the typical two-domain kinase fold with a beta-strand domain (residues 25−138) at the N-terminal end and an alpha-helical domain at the C-terminal end (residues 139−343).
• The ATP-binding site is at the interface of the alpha-helical and beta-strand domain and is bordered by the glycine-rich loop and the hinge.
• The activation loop (residues 200−226) runs along the surface of the substrate binding groove.
• The C-terminal 39 residues (residues 344−382) are outside the core kinase fold and form a small domain that packs against the alpha-helical domain.
• The beta-strand domain consists of seven antiparallel beta-strands: strands 2−6 form a -barrel that is interrupted between strand 4 and 5 by a short helix (residue 96−102) that packs against the beta-barrel.
• This helix is conserved in all kinases, and two of its residues play key roles in the catalytic activity of the enzyme. Arg 96 is involved in the alignment of the two domains. Glu 97 is positioned in the active site and forms a salt bridge with Lys 85, a key residue in catalysis.

The structure of GSK3 .: The N-terminal domain (blue) corresponds to the -strand domain and encompasses residue 25−138. -strand 1 was only visible in one of the two molecules in the asymmetric unit and makes hydrogen bonds with -strand 2, although it is not part of the -barrel. The -helical domain (magenta) corresponds to residues 139−349. Key features of the kinase fold such as the hinge, glycine-rich loop and activation loop are indicated. The area in the box is shown in detail in Fig. 3a and 4. Residues 7−24, 120−126 (in molecule A), 286−300 (in molecule A), 286−290 (in molecule B) and 384−420 were disordered and have not been included in the model. The side chains of residues 31, 33−35 and 37 were not visible, and these residues were modeled as glycine. Residues 46, 91−93, 121−124 and 308 were modeled as alanines. The carbons in A and B chains have a root mean square (r.m.s.) deviation of 0.48 Å after superposition.

Phosphorylation

• GSK3 has two phosphorylation sites that influence the catalytic activity of the protein.
  • Ser 9 is the phosphorylation site for AKT, and the phosphorylation of this residue inactivates GSK3.
  • Phosphorylation of Tyr 216, located on the activation loop, increases the catalytic activity.

Similarity

• Ser/Thr protein kinase family. GSK-3 subfamily.
• Contains 1 protein kinase domain.

Amino Acid Sequence

The sequence GSK3B_HUMAN consists of 420 amino acids.

       10         20         30         40         50         60 

MSGRPRTTSF AESCKPVQQP SAFGSMKVSR DKDGSKVTTV VATPGQGPDR PQEVSYTDTK

       70         80         90        100        110        120 

VIGNGSFGVV YQAKLCDSGE LVAIKKVLQD KRFKNRELQI MRKLDHCNIV RLRYFFYSSG

      130        140        150        160        170        180 

EKKDEVYLNL VLDYVPETVY RVARHYSRAK QTLPVIYVKL YMYQLFRSLA YIHSFGICHR

      190        200        210        220        230        240 

DIKPQNLLLD PDTAVLKLCD FGSAKQLVRG EPNVSYICSR YYRAPELIFG ATDYTSSIDV

      250        260        270        280        290        300 

WSAGCVLAEL LLGQPIFPGD SGVDQLVEII KVLGTPTREQ IREMNPNYTE FKFPQIKAHP

      310        320        330        340        350        360 

WTKVFRPRTP PEAIALCSRL LEYTPTARLT PLEACAHSFF DELRDPNVKL PNGRDTPALF

      370        380        390        400        410        420 

NFTTQELSSN PPLATILIPP HARIQAAAST PTNATAASDA NTGDRGQTNN AASASASNST

Others Details

• Molecular weight: 46744.3
• Theoretical pI: 8.98
• Amino acid composition:

Ala (A) 34 8.1% Arg (R) 27 6.4% Asn (N) 17 4.0% Asp (D) 22 5.2% Cys (C) 9 2.1% Gln (Q) 18 4.3% Glu (E) 19 4.5% Gly (G) 22 5.2% His (H) 7 1.7% Ile (I) 20 4.8% Leu (L) 37 8.8% Lys (K) 23 5.5% Met (M) 5 1.2% Phe (F) 18 4.3% Pro (P) 31 7.4% Ser (S) 32 7.6% Thr (T) 30 7.1% Trp (W) 2 0.5% Tyr (Y) 18 4.3% Val (V) 29 6.9% Asx (B) 0 0.0% Glx (Z) 0 0.0% Xaa (X) 0 0.0%

• Total number of negatively charged residues (Asp + Glu): 41
• Total number of positively charged residues (Arg + Lys): 50

• Atomic composition:

Carbon C 2085 Hydrogen H 3285 Nitrogen N 575 Oxygen O 618 Sulfur S 14

• Formula: C2085H3285N575O618S14
• Total number of atoms: 6577

• Extinction coefficients:

• • Extinction coefficients are in units of M-1 cm-1, at 280 nm.

• • • Ext. coefficient 38320
    • Abs 0.1% (=1 g/l) 0.820, assuming ALL Cys residues appear as half cystines

• • • Ext. coefficient 37820
    • Abs 0.1% (=1 g/l) 0.809, assuming NO Cys residues appear as half cystines

• Estimated half-life:

• • The N-terminal of the sequence considered is M (Met).

• • The estimated half-life is: 30 hours (mammalian reticulocytes, in vitro).

                           >20 hours (yeast, in vivo).
                           >10 hours (Escherichia coli, in vivo).

• Instability index:

• • The instability index (II) is computed to be 29.32
  • This classifies the protein as stable.

• Aliphatic index: 81.05
• Grand average of hydropathicity (GRAVY): -0.319

GOR4 result for : UNK_163320

---